AstraZeneca(US:AZN) Zhong Guo Jing Ji Wang·2025-06-20 03:10Group 1 - The Chinese pharmaceutical industry is entering an innovative development phase, providing more motivation and assurance for AstraZeneca's innovation in China [1] - AstraZeneca announced a $2.5 billion investment to establish a global strategic R&D center in Beijing and expand cooperation, promoting "China Innovation" globally [1] - AstraZeneca's China General Manager highlighted the positive impact of China's high-level opening-up policies on foreign investment and local innovation [1] Group 2 - AstraZeneca has signed a strategic R&D cooperation agreement with China National Pharmaceutical Group, focusing on AI-driven drug research [1] - Since 2023, AstraZeneca has reached licensing cooperation agreements with 14 Chinese innovative pharmaceutical companies, totaling over $23 billion [1] - AstraZeneca's China Medical Industry Fund plays a crucial role in early investments in local biopharmaceutical companies, with a fund size of $550 million and investments in 27 local firms [2] Group 3 - AstraZeneca has introduced over 40 innovative drugs to China in the past 30 years, with 8 new drugs and indications approved this year [2] - By 2030, AstraZeneca expects to launch an additional 20 global new drugs in China [2] - The company has invested over $1.7 billion in manufacturing in China since 2023, establishing global production bases in Wuxi, Taizhou, and Qingdao [2]